Patients with some cancers, autoimmune diseases, and metabolic disorders often endure time-consuming intravenous (IV) infusions to receive the best protein-based treatments available. Because these ...

People living with relapsed or refractory multiple myeloma now have a faster way to receive one of their key treatments. The ...

A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing with Johnson & Johnson’s powerhouse Darzalex, largely because it reached ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...

Lecanemab decision marks first time patients can begin treatment with home administration ...

July 10 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering ...

A team of scientists has uncovered the mechanism of cellular uptake for large and polar drugs and devised a novel strategy to optimize the capacity of drug-delivery into these cells. The team was led ...

NAD+ (nicotinamide adenine dinucleotide) infusions are being used to reverse the effects of aging. They aren’t approved by the FDA, meaning their safety and effectiveness haven’t been evaluated. If ...